

Kanti R Rai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5174015/publications.pdf>

Version: 2024-02-01

105
papers

8,587
citations

331259

21
h-index

71532

76
g-index

106
all docs

106
docs citations

106
times ranked

7535
citing authors

#	ARTICLE	IF	CITATIONS
1	B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	10
2	Activated CLL cells regulate IL-17Fâ€‘producing Th17 cells in miR155-dependent and outcome-specific manners. <i>JCI Insight</i> , 2022, 7, .	2.3	2
3	Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035220.	2.9	28
4	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	2.2	11
5	Chronic lymphocytic leukemiaâ€‘like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2021, 95, 68-80.	0.2	6
6	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	3.3	25
7	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	1.3	12
8	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021, 35, 1037-1052.	3.3	19
9	Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL. <i>Blood</i> , 2021, 138, 2625-2625.	0.6	0
10	Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue. <i>Blood</i> , 2021, 138, 3708-3708.	0.6	0
11	Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL. <i>Blood</i> , 2021, 138, 2622-2622.	0.6	0
12	FcÎ³RIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 106, 306-309.	1.7	1
13	CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. <i>Blood Advances</i> , 2020, 4, 893-905.	2.5	5
14	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 570, 474-479.	13.7	86
15	Mechanism for IL-15â€‘Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. <i>Journal of Immunology</i> , 2019, 202, 2924-2944.	0.4	9
16	Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. <i>Cancer</i> , 2019, 125, 1432-1440.	2.0	68
17	CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019, 134, 477-477.	0.6	4
18	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069

#	ARTICLE	IF	CITATIONS
19	Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2018, 2, e39.	1.2	12
20	Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion. <i>Journal of Immunology</i> , 2018, 201, 1570-1585.	0.4	16
21	Dual Inhibition of PI3K- $\hat{1}$ and PI3K- $\hat{3}$ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model. <i>Blood</i> , 2018, 132, 4420-4420.	0.6	4
22	Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl. <i>Blood</i> , 2018, 132, 392-392.	0.6	1
23	CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms. <i>Blood</i> , 2018, 132, 1836-1836.	0.6	0
24	Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo. <i>Blood</i> , 2018, 132, 3124-3124.	0.6	0
25	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16096.	18.1	363
26	Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation. <i>Molecular Medicine</i> , 2017, 23, 1-12.	1.9	14
27	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2016, 1, 122-131.	2.5	15
28	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016, 1, .	2.3	29
29	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	0.6	102
30	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity andIGHV mutation status. <i>Clinical Immunology</i> , 2016, 172, 44-51.	1.4	11
31	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 216-227.	1.3	15
32	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 85.	6.9	29
33	Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor. <i>Molecular Medicine</i> , 2015, 21, 46-57.	1.9	12
34	Augmenting NF- \hat{B} in poor-risk CLL: A general paradigm for other cancers?. <i>Journal of Experimental Medicine</i> , 2015, 212, 830-831.	4.2	5
35	A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 90-100.	1.3	18
36	TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. <i>Journal of Immunology</i> , 2015, 195, 901-923.	0.4	47

#	ARTICLE	IF	CITATIONS
37	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1713-1713.	0.6	1
38	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation. <i>Blood</i> , 2015, 126, 4155-4155.	0.6	8
39	The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones. <i>Blood</i> , 2015, 126, 4149-4149.	0.6	0
40	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. <i>PLoS ONE</i> , 2014, 9, e90725.	1.1	37
41	In Vivo Evidence That Ibrutinib Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues. <i>Blood</i> , 2014, 124, 1948-1948.	0.6	2
42	CLL Sera Drive Maturation of Normal Monocytes to M2-like Macrophages By Direct and Indirect Mechanisms. <i>Blood</i> , 2014, 124, 1970-1970.	0.6	1
43	Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results. <i>Blood</i> , 2014, 124, 3063-3063.	0.6	9
44	Ibrutinib Inhibits Concomitant TLR and BCR- Driven Proliferation of Chronic Lymphocytic Leukemia Cells and Overrides the Supportive Survival-Promoting Effects of Microenvironmental Signals. <i>Blood</i> , 2014, 124, 3310-3310.	0.6	3
45	Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIGÂ®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (ChI), or Chlorambucil/Rituximab (ChIR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 3343-3343.	0.6	10
46	Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIGÂ®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 5653-5653.	0.6	6
47	Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia. <i>Blood</i> , 2014, 124, 24-24.	0.6	4
48	Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells. <i>Blood</i> , 2014, 124, 3279-3279.	0.6	0
49	TLR-9 and IL-15-Driven Clonal Expansion of B-CLL Cells. <i>Blood</i> , 2014, 124, 1937-1937.	0.6	0
50	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3KÎ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation. <i>Blood</i> , 2013, 122, 1632-1632.	0.6	12
51	Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability. <i>Blood</i> , 2013, 122, 4176-4176.	0.6	6
52	A Phase 1 Study Of The Selective PI3KÎ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4180-4180.	0.6	10
53	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013, 122, 525-525.	0.6	32
54	Apparent Involvement Of The Interferon, RNA Processing, and Wnt Signaling Pathways In Monoclonal B Lymphocytosis. <i>Blood</i> , 2013, 122, 4157-4157.	0.6	0

#	ARTICLE	IF	CITATIONS
55	A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4129-4129.	0.6	30
56	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 119-119.	0.6	1
57	Concomitant, T-Independent TLR9-Mediated and BCR-Mediated Activation Provides Signals For Optimal Telomerase Induction In Chronic Lymphocytic Leukemia Cells Regardless Of IGHV Mutation Status. <i>Blood</i> , 2013, 122, 4142-4142.	0.6	0
58	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. <i>Haematologica</i> , 2012, 97, 599-607.	1.7	65
59	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012, 120, 4802-4811.	0.6	52
60	Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 316-316.	0.6	0
61	Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. <i>Blood</i> , 2012, 120, 2545-2545.	0.6	4
62	CLL Cell Viability Promoted by Myosin Heavy Chain IIA Exposed Apoptotic Cells is BTK-dependent. <i>Blood</i> , 2012, 120, 1767-1767.	0.6	0
63	Fludarabine Versus Chlorambucil: Is the Debate Over?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S7-S9.	0.2	7
64	Advances in the Clinical Staging of Chronic Lymphocytic Leukemia. <i>Clinical Chemistry</i> , 2011, 57, 1771-1772.	1.5	8
65	Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. <i>Molecular Medicine</i> , 2011, 17, 1374-1382.	1.9	140
66	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 5201-5210.	0.6	110
67	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011, 118, 288-288.	0.6	3
68	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. <i>Blood</i> , 2011, 118, 289-289.	0.6	8
69	Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. <i>Blood</i> , 2011, 118, 291-291.	0.6	5
70	Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells. <i>Blood</i> , 2011, 118, 975-975.	0.6	4
71	TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,. <i>Blood</i> , 2011, 118, 3690-3690.	0.6	1
72	Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones. <i>Blood</i> , 2011, 118, 624-624.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Longitudinal Analyses of CXCR4dimCD5brCD19+ Fractions of Chronic Lymphocytic Leukemia Clones Reveal Features Consistent with a Source of Clonal Heterogeneity. <i>Blood</i> , 2011, 118, 804-804.	0.6	9
74	Perspectives Among Primary Care Providers and Hematologist/Oncologists in the Coordination of Care for Patients with Hematologic Malignancies. <i>Blood</i> , 2011, 118, 3156-3156.	0.6	0
75	Targeted Oligonucleotide Array Assessment of Genomic Copy Number Alterations for Risk Stratification in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1773-1773.	0.6	0
76	Identification of Distinct Cytokine and Chemokine Clusters That Correlate with Outcome In B-Cell Chronic Lymphocytic Leukemia: Implications for Disease Pathogenesis. <i>Blood</i> , 2010, 116, 1368-1368.	0.6	2
77	Elevated IL-17 Producing Cells (Th17 and Non-Th17) In Different CLL Microenvironments: Correlation with Overall Survival, Prognostic Relevance and Phenotypic Heterogeneity. <i>Blood</i> , 2010, 116, 2442-2442.	0.6	1
78	CCR4:CCL17 Interaction Influences TLR-9 Mediated Cell Survival and Proliferation In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3593-3593.	0.6	9
79	Provision of Human Multimeric sCD40L to Immune Deficient NSG Mice Permits Efficient and Effective Adoptive Transfer and Proliferation of CLL Cells In Vivo. <i>Blood</i> , 2010, 116, 2430-2430.	0.6	0
80	Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients. <i>Blood</i> , 2010, 116, 1392-1392.	0.6	3
81	Detection of Activation-Induced Cytidine Deaminase RNA In CLL Cells Correlates with Shorter Patient Survival and High Numbers of CD38+ Cells. <i>Blood</i> , 2010, 116, 2415-2415.	0.6	0
82	Somatic Hypermutation In Stereotyped Subset 4 BCRs/mAbs of CLL Patients, Expressing IGHV4-34 gene, Edit Anti-DNA Reactivity. <i>Blood</i> , 2010, 116, 2444-2444.	0.6	1
83	Chronic Lymphocytic Leukemia B Cells Variably Express Functional Activation-Induced Cytosine Deaminase Protein. <i>Blood</i> , 2010, 116, 378-378.	0.6	0
84	B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells Unresponsive to CD180 Ligation Fail to Respond to Anti-IgM Stimulation as Well. <i>Blood</i> , 2010, 116, 3582-3582.	0.6	4
85	Some CLL Cells Bind Myosin-Exposed Apoptotic Cells. Exposure of Cytoplasmic Myosin Results From Transfer of Caspase-3 Dependent Cleavage Products to the Outer Cell Membrane. <i>Blood</i> , 2010, 116, 3900-3900.	0.6	0
86	Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo. <i>Blood</i> , 2010, 116, 2441-2441.	0.6	0
87	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. <i>Blood</i> , 2009, 114, 3615-3624.	0.6	37
88	Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.. <i>Blood</i> , 2009, 114, 539-539.	0.6	8
89	Correlation of Leukemia-Cell Birth Rate Measured by Heavy Water Labeling with Other Prognostic Markers in Early Stage Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 60-60.	0.6	2
90	Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL.. <i>Blood</i> , 2009, 114, 4369-4369.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Autologous Human T Cells and Allogeneic Antigen-Presenting Cells Permit Effective Adoptive Transfer of B-CLL Cells Into Immune Deficient Mice.. Blood, 2009, 114, 2326-2326.	0.6	0
92	Th-17/IL-17 Axis in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2357-2357.	0.6	0
93	Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study.. Blood, 2009, 114, 1614-1614.	0.6	0
94	CCR4: TARC Interaction Provides Supplementary Pro-Survival and Proliferative Signals to Chronic Lymphocytic Leukemia Cells.. Blood, 2009, 114, 2327-2327.	0.6	0
95	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute's Working Group 1996 guidelines. Blood, 2008, 111, 5446-5456.	0.6	2,887
96	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. Molecular Medicine, 2008, 14, 665-674.	1.9	174
97	5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect. Blood, 2008, 112, 4201-4201.	0.6	2
98	Frequently Occurring B-CLL Antibodies Recognize Apoptotic Cells That Expose Non-Muscle Myosin Heavy Chain IIA. Blood, 2008, 112, 3123-3123.	0.6	0
99	Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies.. Blood, 2007, 110, 1113-1113.	0.6	2
100	B-CLL Antibodies Encoded by Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Non-Muscle Myosin Heavy Chain IIA.. Blood, 2007, 110, 739-739.	0.6	0
101	Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells.. Blood, 2006, 108, 2813-2813.	0.6	11
102	Remarkable Differences in Cellular Activation State and Migratory and Proliferative Potential among Clonal Cells Derived from Different Tissues of Chronic Lymphocytic Leukemia Patients.. Blood, 2006, 108, 2817-2817.	0.6	0
103	Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).. Blood, 2006, 108, 2085-2085.	0.6	0
104	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation, 2005, 115, 755-764.	3.9	515
105	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1840-1847.	0.6	2,291